Oncobiologics (Four Cancer Biosimilars) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Oncobiologics (Four Cancer Biosimilars) General Information

Description

Four cancer biosimilars in China. The four biosimilars are manufactured at Huahai's biologicals facility. The assets include generic versions of Humira (adalimumab biosimilar) indicated for rheumatoid arthritis, crohns, ulcerative colitis and psoriasis, Rituxan, indicated for non-hodgkin lymphoma, Avastin, colorectal cancer and lung cancer, Herceptin, indicated for breast cancer and colorectal cancer and Erbitux, indicated for metastatic colorectal cancer, head and neck cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 7 Clarke Drive
  • Cranbury, NJ 08512
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Commercial Products
Biotechnology
Acquirer
Huahai US
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • 7 Clarke Drive
  • Cranbury, NJ 08512
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncobiologics (Four Cancer Biosimilars) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncobiologics (Four Cancer Biosimilars)‘s full profile, request access.

Request a free trial

Oncobiologics (Four Cancer Biosimilars) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncobiologics (Four Cancer Biosimilars)‘s full profile, request access.

Request a free trial

Oncobiologics (Four Cancer Biosimilars) FAQs

  • Where is Oncobiologics (Four Cancer Biosimilars) headquartered?

    Oncobiologics (Four Cancer Biosimilars) is headquartered in Cranbury, NJ.

  • What industry is Oncobiologics (Four Cancer Biosimilars) in?

    Oncobiologics (Four Cancer Biosimilars)’s primary industry is Buildings and Property.

  • Is Oncobiologics (Four Cancer Biosimilars) a private or public company?

    Oncobiologics (Four Cancer Biosimilars) is a Private company.

  • What is Oncobiologics (Four Cancer Biosimilars)’s current revenue?

    The current revenue for Oncobiologics (Four Cancer Biosimilars) is .

  • Who are Oncobiologics (Four Cancer Biosimilars)’s investors?

    Outlook Therapeutics has invested in Oncobiologics (Four Cancer Biosimilars).

  • When was Oncobiologics (Four Cancer Biosimilars) acquired?

    Oncobiologics (Four Cancer Biosimilars) was acquired on 01-Mar-2013.

  • Who acquired Oncobiologics (Four Cancer Biosimilars)?

    Oncobiologics (Four Cancer Biosimilars) was acquired by Huahai US.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »